Vycor Medical Inc (VYCO) stock
Close on Oct 19, 2026Market cap $2.24MP/E –Yield –
Vycor Medical Inc grew revenue 1.6% to $1.81M over the twelve months to Jun 30, 2026. Operating income rose 113.8% to $48.22K, moving the operating margin from 1.3% to 2.7%. Free cash flow was -$18.70K, down 134.1% from a year earlier. At the latest close the market valued the company at $2.24M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.24M
- P/E ratio
- –
- Price to sales
- 1.24
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -0.84%
Fundamentals
- Revenue
- $1.81M
- Net income
- -$59.93K
- EPS, diluted
- $0.00
- Free cash flow
- -$18.70K
- Book value per share
- -$0.13
- Diluted shares
- 33M
Trading
- Next earnings
- Nov 13, 2026 (estimated, before the open)
- Previous close
- $0.07
- Open
- $0.07
- Day's range
- $0.07 – $0.07
- Volume
- 0
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | VYCO | S&P 500 | Difference | VYCO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +0.6% | −0.6 pts | ||
| 3 months | -2.9% | +3.4% | −6.3 pts | ||
| Year to date | -44.6% | +13.3% | −57.9 pts | ||
| 1 year | -46.0% | +16.6% | −62.6 pts | ||
| 3 years | -29.5% | +86.4% | −115.9 pts | -11.0% | +23.1% |
| 5 years | -47.7% | +81.9% | −129.5 pts | -12.1% | +12.7% |
| 10 years | -73.2% | +318.9% | −392.1 pts | -12.3% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vycor Medical filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Vycor Medical
Surgical & Medical Instruments & Apparatus
Vycor Medical, Inc. operates within the medical device industry across two distinct divisions: Vycor Medical and NovaVision. The Vycor Medical division designs, develops, and commercializes medical devices tailored for neurosurgery, featuring its ViewSite Brain Access System for surgical access and retraction during brain and spine procedures. NovaVision supplies computer-based, non-invasive rehabilitation therapies designed for patients suffering from visual impairments caused by neurological brain trauma, such as strokes, utilizing products like Vision Restoration Therapy and NeuroEyeCoach.
Company profile, executives and historyVycor Medical stock: common questions
What is Vycor Medical's stock price?
VYCO closed at $0.07 on Oct 19, 2026, up 0.00% on the day.
What is Vycor Medical's market cap?
Vycor Medical was worth $2.24M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is VYCO's P/E ratio?
Vycor Medical lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does Vycor Medical make?
Vycor Medical reported revenue of $1.81M for the twelve months to Jun 30, 2026, up 1.6% from a year earlier.
Does Vycor Medical pay a dividend?
No. Vycor Medical has not paid a cash dividend over the last twelve months.
When does Vycor Medical report earnings next?
Vycor Medical is expected to report Q3 FY2026 results on Nov 13, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has VYCO stock performed over the past year?
Including dividends, VYCO returned -46.0% over the past year, against +16.6% for the S&P 500.
Who are Vycor Medical's competitors?
Companies most similar to Vycor Medical by business, industry and size include VJET, OSRH, PLSE, FEMY, SINT.
See a number that looks wrong?